Evidence map›Paper›PMID 36067450›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Oral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor.

Ryo Nishihara, Akihiko Shimomura, Chikako Shimizu

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryo NishiharaRyo Nishihara, MD, Akihiko Shimomura, MD, PhD, and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Akihiko ShimomuraRyo Nishihara, MD, Akihiko Shimomura, MD, PhD, and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0002-2557-8170
Chikako ShimizuRyo Nishihara, MD, Akihiko Shimomura, MD, PhD, and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0003-1448-5865
Shimizu (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsReceptors, EstrogenCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Estrogen AntagonistsEstrogen Receptor alphaFemaleHumansProtein Kinase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Estrogen AntagonistsEstrogen Receptor alphaProtein Kinase InhibitorsReceptors, Estrogen

Identifiers

PMID36067450
OpenAlexW4294841232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.